Format

Send to

Choose Destination
J Autism Dev Disord. 2018 Oct 31. doi: 10.1007/s10803-018-3808-2. [Epub ahead of print]

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.

Author information

1
Neuropediatric Unit, Shaare Zedek Medical Center, 12 Bayit Street, 91031, Jerusalem, Israel. aaran@szmc.org.il.
2
Clallit HMO (Kupat Holim), Jerusalem, Israel.
3
Neuropediatric Unit, Shaare Zedek Medical Center, 12 Bayit Street, 91031, Jerusalem, Israel.

Abstract

Anecdotal evidence of successful cannabis treatment in autism spectrum disorder (ASD) are accumulating but clinical studies are lacking. This retrospective study assessed tolerability and efficacy of cannabidiol-rich cannabis, in 60 children with ASD and severe behavioral problems (age = 11.8 ± 3.5, range 5.0-17.5; 77% low functioning; 83% boys). Efficacy was assessed using the Caregiver Global Impression of Change scale. Adverse events included sleep disturbances (14%) irritability (9%) and loss of appetite (9%). One girl who used higher tetrahydrocannabinol had a transient serious psychotic event which required treatment with an antipsychotic. Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients. This preliminary study supports feasibility of CBD-based cannabis trials in children with ASD.

KEYWORDS:

Autism spectrum disorder; Cannabidiol; Disruptive behavior; Medical cannabis; Medical marijuana

PMID:
30382443
DOI:
10.1007/s10803-018-3808-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center